Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × Cisplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 484 Squamous Cell Carcinoma of Head and Neck 240 Head and Neck Neoplasms 227 Lung Neoplasms 220 Uterine Cervical Neoplasms 158 Stomach Neoplasms 153 Esophageal Neoplasms 147 Nasopharyngeal Carcinoma 121 Urinary Bladder Neoplasms 101 Neoplasms 101 Esophageal Squamous Cell Carcinoma 101 Small Cell Lung Carcinoma 95 Breast Neoplasms 84 Ovarian Neoplasms 82 Neoplasm Metastasis 75 Carcinoma, Squamous Cell 72 Pancreatic Neoplasms 70 Biliary Tract Neoplasms 65 Cholangiocarcinoma 64 Mesothelioma, Malignant 54 Adenocarcinoma Of Esophagus 48 Oropharyngeal Neoplasms 47 Carcinoma 46 Recurrence 44 Carcinoma, Ovarian Epithelial 43 Parkinson Disease 4, Autosomal Dominant Lewy Body 41 Lymphoma 37 Adenocarcinoma of Lung 37 Gallbladder Neoplasms 36 Carcinoma, Transitional Cell 35

Interventions

pembrolizumab 2 enfortumab vedotin 2 Gemcitabine 2 Carboplatin 2 zimberelimab 1 sacituzumab govitecan 1 olaparib 1 avelumab 1 Oxaliplatin 1 Nivolumab 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡